Effects of treatment of hyperthyroidism on glucose homeostasis, insulin secretion, and markers of bone turnover

Endocrine Practice

Volumn 12, Issue 2, 2006, Pages 121-130

  Al Shoumer, Kamal A S ^a,b   Vasanthy, Bagavathy A ^b   Al Zaid, Mona M ^a  

^a MUBARAK AL KABEER HOSPITAL   (Kuwait)

^b KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; C PEPTIDE; CALCIUM; ICTP PEPTIDE; INSULIN; OSTEOCALCIN; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I CARBOXY TERMINAL PEPTIDE; PROINSULIN;

ADULT; ARTICLE; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTHYROIDISM; INSULIN RESISTANCE; MALE; OSTEOLYSIS; SECRETION; THYROTOXICOSIS;

ADULT; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BONE RESORPTION; C-PEPTIDE; CALCIUM; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTHYROIDISM; INSULIN; INSULIN RESISTANCE; MALE; OSTEOCALCIN; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROINSULIN; THYROTOXICOSIS;

EID: 33745409180     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.12.2.121     Document Type: Article

References (42)

1. Hales CN, Hyams DE. Plasma concentrations of glucose, non-esterified fatty acid, and insulin during oral glucosetolerance tests in thyrotoxicosis. Lancet. 1964;39:69-71.
2. Dimitriadis G, Baker B, Marsh H, et al. Effects of thyroid hormone excess on action, secretion, and metabolism of insulin in humans. Am J Physiol. 1985;248(5 Pt 1): E593-E601.
3. Pestell R, Alford F, Ramos R, Sawyer S, Best J, Ward G. Insulin secretion, insulin sensitivity and glucose-mediated glucose disposal in thyrotoxicosis: a minimal model analysis. Clin Endocrinol (Oxf). 1990;33:481-493.
4. Wennlund A, Felig P, Hagenfeldt L, Wahren J. Hepatic glucose production and splanchnic glucose exchange in hyperthyroidism. J Clin Endocrinol Metab. 1986;62:174-180.
5. Wu TJ, Huang SM, Taylor RL, Kao PC. Abnormal proinsulin levels in thyroid dysfunction measured by a sensitive proinsulin immunochemiluminoassay. Ann Clin Lab Sci. 1998;28:82-87.
6. Malaisse WJ, Malaisse-Lagae F, McGraw EF. Effects of thyroid function upon insulin secretion. Diabetes. 1967; 16:643-646.
7. Lenzen S. Dose-response studies on the inhibitory effect of thyroid hormones on insulin secretion in the rat. Metabolism. 1977;27:81-88.
8. Wolf E, Eisenstein AB. Portal vein blood insulin and glucagon are increased in experimental hyperthyroidism. Endocrinology. 1981;108:2109-2113.
9. Osei K, Falko JM, O'Dorisio TM, Adam DR. Decreased serum C-peptide/insulin molar ratios after oral glucose ingestion in hyperthyroid patients. Diabetes Care. 1984;7:471-475.
10. Taylor R, McCulloch AJ, Zeuzem S, Gray P, Clark F, Alberti KG. Insulin secretion, adipocyte insulin binding and insulin sensitivity in thyrotoxicosis. Acta Endocrinol (Copenh). 1985;109:96-103.
11. Roti E, Braverman LE, Robuschi G, et al. Basal and glucose-and arginine-stimulated serum concentrations of insulin, C-peptide, and glucagon in hyperthyroid patients. Metabolism. 1986;35:337-342.
12. Beer SF, Parr JH, Temple RC, Hales CN. The effect of thyroid disease on proinsulin and C-peptide levels. Clin Endocrinol (Oxf). 1989;30:379-383.
13. Sestoft L, Heding LG. Hypersecretion of proinsulin in thyrotoxicosis. Diabetologia. 1981;21:103-107.
14. Cohen P, Barzilai N, Barzilai D, Karnieli E. Correlation between insulin clearance and insulin responsiveness: studies in normal, obese, hyperthyroid, and Cushing's syndrome patients. Metabolism. 1986;35:744-749.
15. Cavallo-Perin P, Bruno A, Boine L, Cassader M, Lenti G, Pagano G. Insulin resistance in Graves' disease: a quantitative in-vivo evaluation. Eur J Clin Invest. 1988;18: 607-613.
16. Bech K, Damsbo P, Eldrup E, et al. Beta-cell function and glucose and lipid oxidation in Graves' disease. Clin Endocrinol (Oxf). 1996;44:59-66.
17. Meunier PJ, Bianchi CG, Edouard CM, Bernard JC, Coupron PM, Vignon GE. Bony manifestations of thyrotoxicosis. Orthop Clin North Am. 1972;3:745-774.
18. Melsen F, Mosekilde L. Morphometric and dynamic studies of bone changes in hyperthyroidism. Acta Pathol Microbiol Immunol Scand [A]. 1977;85:141-150.
19. Mosekilde L, Eriksen EF, Charles P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am. 1990;19:35-63.
20. Sato K, Han DC, Fujii Y, Tsushima T, Shizume K. Thyroid hormone stimulates alkaline phosphatase activity in cultured rat osteoblastic cells (ROS 17/2.8) through 3,5,3′-triiodo-L-thyronine nuclear receptors. Endocrinology. 1987;120:1873-1881.
21. Ohishi K, Ishida H, Nagata T, et al. Thyroid hormone suppresses the differentiation of osteoprogenitor cells to osteoblasts, but enhances functional activities of mature osteoblasts in cultured rat calvaria cells. J Cell Physiol. 1994;161:544-552.
22. Legovini P, De Menis E, Da Rin G, et al. Increased serum levels of carboxyterminal propeptide of type 1 collagen (P1CP) in hyperthyroidism. Horm Metab Res. 1994;26: 334-337.
23. Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD. Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab. 1994;78: 955-959.
24. Langdahl BL, Loft AG, Eriksen EF, Mosekilde L, Charles P. Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy. Thyroid. 1996;6: 161-168.
25. Rosen CJ, Adler RA. Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. J Clin Endocrinol Metab. 1992;75:1531-1534.
26. Diamond T, Vine J, Smart R, Butler P. Thyrotoxic bone disease in women: a potentially reversible disorder. Ann Intern Med. 1994;120:8-11.
27. Horwitz DL, Kuzuya H, Rubenstein AH. Circulating serum C-peptide: a brief review of diagnostic implications. N Engl J Med. 1976;295:207-209.
28. Haffner SM, Miettenen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care. 1997;20:1087-1092.
29. Diabetes mellitus: report of a WHO study group. World Health Organ Tech Rep Ser. 1985;727:9-17.
30. Report of the Expert Committee on Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997; 20:1183-1197.
31. Gonzalo MA, Grant C, Moreno I, et al. Glucose tolerance, insulin secretion, insulin sensitivity and glucose effectiveness in normal and overweight hyperthyroid women. Clin Endocrinol (Oxf). 1996;45:689-697.
32. Tene C, Zarate A, Basurto L, et al. Correction of insulin resistance in methimazole-treated patients with Graves' disease. Rev Invest Clin. 2001;53:531-535.
33. Jap TS, Ho LT, Won JG. Insulin secretion and sensitivity in hyperthyroidism. Horm Metab Res. 1989;21:261-266.
34. Lenzen S, Kucking H. Inhibition of insulin secretion by L-thyroxine and D-thyroxine treatment in rats under the influence of drugs affecting the adrenergic nervous system. Acta Endocrinol (Copenh). 1982;100:527-533.
35. Pantazi H, Papapetrou PD. Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J Clin Endocrinol Metab. 2000;85:1099-1106.
36. Allain TJ, McGregor AM. Thyroid hormones and bone. J Endocrinol. 1993;139:9-18.
37. Akalin A, Colak O, Alatas O, Efe B. Bone remodelling markers and serum cytokines in patients with hyperthyroidism. Clin Endocrinol (Oxf). 2002;57:125-129.
38. Mundy GR, Shapiro JL, Bandelin JG, Canalis EM, Raisz LG. Direct stimulation of bone resorption by thyroid hormones. J Clin Invest. 1976;58:529-534.
39. Rizzoli R, Poser J, Bürgi U. Nuclear thyroid hormone receptors in cultured bone cells. Metabolism. 1986;35:71-74.
40. Abu EO, Bord S, Horner A, Chatterjee UK, Compston JE. The expression of thyroid hormone receptor in human bone. Bone. 1997;21:137-142.
41. Charles P, Mosekilde L, Risteli L, Risteli J, Eriksen EF. Assessment of bone remodeling using biochemical indicators of type 1 collagen synthesis and degradation: relation to calcium kinetics. Bone Miner. 1994;24:81-94.
42. Kent NG. Markers of bone turnover. J Int Fed Clin Chem. 1997;9:31-35.